MaxCyte, Inc (MXCT) Files up to $100M IPO

MaxCyte, Inc (NASDAQ: MXCT) has files an up to $100,000,000 IPO.

The company describes itself as: "We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization."

Cowen, Stifel and William Blair will serve as underwriters.

You May Also Be Interested In

• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut
• TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'
• Sonida Senior Living (SNDA) files for 17.11M share offering by selling stockholders